STOCK TITAN
  1. Home
  2. News
  3. AIMDW

Ainos Inc - AIMDW STOCK NEWS

Welcome to our dedicated news page for Ainos (Ticker: AIMDW), a resource for investors and traders seeking the latest updates and insights on Ainos.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ainos's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ainos's position in the market.

News
Ainos Reports Full Year 2023 Financial Results
Rhea-AI Summary
Ainos, Inc. reports financial results for 2023, focusing on strategic pivot towards VELDONA and AI-powered point-of-care testing. The company advances VELDONA drug candidates to Phase III clinical studies and expands the market of AI Nose-powered VOC-sensing technology with strategic partners NISD and Inabata.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
earnings
-
News
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Rhea-AI Summary
Ainos, Inc. has submitted a complete response to the U.S. FDA for a Phase II trial of its low-dose oral interferon-alpha formulation, VELDONA, intended for the treatment of mild COVID-19 symptoms. The company's Phase II trial is expected to involve a multicenter, parallel, randomized study conducted in Taiwan during the third quarter of 2024. Ainos has successfully addressed the deficiencies identified by the FDA, accelerating the timeline for its clinical trials. The updated Chemistry, Manufacturing, and Controls information indicates that the stability of VELDONA can exceed the minimum shelf life of biologicals. Ainos plans to submit additional IND applications for the treatment of oral warts in HIV-seropositive patients and Sjögren's syndrome. The company aims to expand its VELDONA platform for the treatment of other viral infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.85%
Tags
clinical trial covid-19
-
News
Ainos Announces $1.75 Million Follow-On Funding
Rhea-AI Summary
Ainos, Inc. (NASDAQ:AIMD) has announced a $1.75 million follow-on funding from Lind Global Fund II LP, with plans to use the proceeds for VELDONA IND preparation and AI Nose VOC platform development. The funding is in the form of an amendment to a Senior Secured Convertible Promissory Note, with the Investor being granted five-year warrants equal to 75% of the funded amount at an initial exercise price of $2.16 per share of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.34%
Tags
none
News
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) regained compliance with NASDAQ's minimum bid price requirement after its common stock maintained a closing bid price of $1.00 or more for at least 10 consecutive business days, following a previous non-compliance notice on January 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
none
-
News
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announces collaboration with Nisshinbo Micro Devices Inc. and Taiwan Inabata Sangyo Co. to develop AI Nose technology for mass production readiness targeted for 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial AI
-
News
Ainos, Inc. Announces Stock Consolidation
Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announces a consolidation (reverse stock split) of its outstanding shares of common stock, effective December 14, 2023. The new shares of common stock will trade under a new CUSIP number, with the ticker symbol AIMD remaining unchanged. The number of outstanding common shares will be approximately 4,677,898 shares, with no fractional shares issued. Holders of fractional shares will be paid out in cash. Instructions for exchanging existing stock certificates or receiving cash proceeds will be provided by the Company's transfer agent, Equiniti Trust Company, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
none
News
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Rhea-AI Summary
Ainos, Inc. (AIMD, AIMDW) collaborates with Swiss Pharmaceutical Co., Ltd. to complete the manufacturing of a GMP Clinical Batch of VELDONA® investigational new drugs. Ainos intends to submit Investigational New Drug Applications to the U.S. FDA for multiple candidates including HIV Oral Warts Orphan Drug, Sjogren's Syndrome, the Common Cold, and COVID-19 during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
News
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Rhea-AI Summary
Ainos, Inc. (AIMD, AIMDW) announced positive top-line data from three clinical studies for its VELDONA low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients. The results partially fulfill hypotheses, demonstrating the formulation's superior efficacy compared to a placebo. Ainos plans to pursue a pre-IND meeting with the U.S. FDA ahead of planned Phase III clinical studies for the drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
clinical trial
-
News
Ainos Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Ainos, Inc. (NASDAQ: AIMD, AIMDW) announced its Q3 2023 financial results, showing a transition away from COVID-19 test kits and focusing on VELDONA® Pet cytoprotein supplements. The company also reported decreased revenues but expects a boost in Q4 from VELDONA® Pet sales. The announcement highlighted a decrease in R&D expenses and a recent $3 million private placement to fund its business strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
earnings
News
Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA
Rhea-AI Summary
Ainos and SIDSCO will collaborate to develop new animal drugs based on Ainos' VELDONA® low-dose oral interferon. A clinical study will be conducted to investigate VELDONA®'s efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administration. Ainos aims to expand its product line into the global pet care market through this partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
clinical trial
Stock AIMDW logo
Ainos Inc

Nasdaq:AIMDW

AIMDW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

AIMDW Stock Data

2.56M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
San Diego